News
EMA positive opinion for ViiV’s cabotegravir
ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for its cabotegravir therapy.